Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care? - Wikidata - wikimedia - TriplyDB

Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

http://www.wikidata.org/entity/Q37989006

about

Current Strategies for the Detection of Minimal Residual Disease in Childhood Acute Lymphoblastic Leukemia Plasma Hsp90 Level as a Marker of Early Acute Lymphoblastic Leukemia Engraftment and Progression in Mice Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.Minimal Residual Disease in AML: Why Has It Lagged Behind Pediatric ALL?Clinical significance of minimal residual disease in patients with acute leukaemia undergoing haematopoietic stem cell transplantation.Clinical implications and prognostic role of minimal residual disease detection in follicular lymphoma Impact of minimal residual disease, detected by flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute lymphoblastic leukemia.Minimal Residual Disease and Childhood Leukemia: Standard of Care Recommendations From the Pediatric Oncology Group of Ontario MRD Working Group.Significance of recurrence of minimal residual disease detected by multi-parameter flow cytometry in patients with acute lymphoblastic leukemia in morphological remission.Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity.

P2860

Q26751269-24CC759A-0725-496F-B8B1-E70A4B1A6750 Q27304789-F0FF0E51-9711-45F2-B79B-30ABC1FB75F3 Q33794311-2B48B93F-4A1C-48A9-A884-F7DDC0849605 Q35992927-20EDFC30-EFC1-4387-81FE-B4EE7B688774 Q38105123-2129AC74-0BEB-40F5-B4CD-9221C608ADAF Q38111389-372DE83B-5359-4D71-A802-693F3D811070 Q38681322-8E1ED9B9-7B29-45A6-BE04-0F10BC3F7F79 Q38749564-1F7453EE-5941-4CD5-879C-A1366CF30CE1 Q40396529-90820E9D-AD0B-4F2C-86E1-FF76ACAB50CA Q45423288-CB2B61B4-1725-4D1B-80A2-3148B2F63D35

P2860

Should minimal residual disease monitoring in acute lymphoblastic leukemia be standard of care?

http://www.wikidata.org/entity/Q37989006

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

Should minimal residual diseas ...... leukemia be standard of care?

@en

Should minimal residual diseas ...... leukemia be standard of care?

@nl

type

label

Should minimal residual diseas ...... leukemia be standard of care?

@en

Should minimal residual diseas ...... leukemia be standard of care?

@nl

prefLabel

Should minimal residual diseas ...... leukemia be standard of care?

@en

Should minimal residual diseas ...... leukemia be standard of care?

@nl

P1433

Q37989006-5E0AB749-EC78-418A-B0CC-D3CF0FF98158

P1476

Q37989006-59C17D2A-8C15-4A1C-B64C-4FA7C958BAB5

P2093

Q37989006-EB6B9F88-644F-4854-AC9F-819D11CF2A82

P2860

Q37989006-1E7E907C-705A-47EC-B4BA-A4D949359800

Q37989006-1EA53075-B965-43C4-9BFB-058577464A0C

Q37989006-2208829B-43D6-43B6-B2F2-E227A4D968A5

Q37989006-2B205822-B522-4B98-98B4-F9336B3F04C6

Q37989006-2C0FD665-2C37-4714-B205-93A4CB608DA9

Q37989006-2DCD206D-8FE2-4B34-B656-387813FEBD7A

Q37989006-346926AB-E412-4E22-8975-B3241820695D

Q37989006-3B0E329E-A592-4316-8393-8F9748943102

Q37989006-40863D5B-D19D-4FA3-A030-AAAA4E3120A4

Q37989006-411ECAFB-C1F9-422F-8E6D-3FC6566D394C

P2888

Q37989006-0E4452D1-56A5-411C-90F3-500149E5DF33

P304

Q37989006-F128EF39-80E0-4891-A61A-721DD69657E7

P31

Q37989006-82D76FCD-1457-4D66-A5D2-EE0B97EBA222

P356

Q37989006-5B980133-6585-4120-9067-A1C1603FDF02

P433

Q37989006-33E6643D-79B8-4FC8-9384-93DCDF99B12D

P478

Q37989006-070D0D1B-5A27-4A1F-9BED-700C89D3DC64

P577

Q37989006-EFF0D251-3407-4864-BCDE-D56AA15501FA

P698

Q37989006-C9285FB1-F92A-4DE5-B214-3A731FE26AEC

P921

Q37989006-BE1F43B8-7CAD-4BE8-8A0D-FDA3043BC1AE

P356

S11899-012-0115-4

P1433

Current hematologic malignancy reports

P1476

Should minimal residual diseas ...... leukemia be standard of care?

@en

P2093

Dario Campana

http://www.w3.org/2001/XMLSchema#string

P2860

Treating childhood acute lymphoblastic leukemia without cranial irradiation

Genes contributing to minimal residual disease in childhood acute lymphoblastic leukemia: prognostic significance of CASP8AP2

Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia

Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials.

Measurement and clinical monitoring of human lymphocyte clonality by massively parallel VDJ pyrosequencing

Diagnosis of chronic myeloid and acute lymphocytic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro.

Early T-cell precursor leukaemia: a subtype of very high-risk acute lymphoblastic leukaemia

Detection and monitoring of normal and leukemic cell populations with hierarchical clustering of flow cytometry data.

Detection of minimal disease in hematopoietic malignancies of the B-cell lineage by using third-complementarity-determining region (CDR-III)-specific probes.

Outcome prediction in childhood acute lymphoblastic leukaemia by molecular quantification of residual disease at the end of induction.

P2888

s11899-012-0115-4

P304

170-177

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11899-012-0115-4

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P577

2012-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22373809

http://www.w3.org/2001/XMLSchema#string

P921